Jordi Remon, Thoracic Oncologist at CIOCC Barcelona, shared a post on X:
“Uncommon / PACC EGFR mut NSCLC are 10% of all EGFRm.
Afatinib is the unique drug approved in this subset. Enozertinib (ORIC-114):promising activity in PACC EGFRm in 3L with intracranial activity
Other ‘competitors’: furmonertinib, zipalertinib, amivantamab+lazertinib.”
More posts about ESMO ASIA 25.
